Imprivata Achieves 51 Percent Single Sign-on Market Share Amongst U.S. Hospitals Using McKesson Paragon or Horizon EMR Systems, According to HIMSS Analytics

Published on:

Lexington, MA, July 30, 2014 -- Imprivata® (NYSE: IMPR), a leading provider of authentication, access management and secure communications solutions for the healthcare industry, today announced that Imprivata OneSign® is the most widely selected single sign-on (SSO) solution amongst U.S. hospitals using McKesson Paragon or Horizon electronic medical records (EMR) systems with a 51 percent market share (an increase of about 11 percent in the last 12 months), according to HIMSS Analytics data. Imprivata will showcase its SSO, authentication and access management solutions as well as Imprivata Cortext®, the secure communications platform for healthcare, in booth #713 at InSight365: 2014 Annual Conference (August 5-8, 2014 in Indianapolis, Ind.).

In addition, Imprivata customer Philip Bierdz, infrastructure manager at Riverside Medical Center (Bourbonnais, Ill.), will deliver a presentation titled “Single Sign-on: Is it Worth the Investment?” (session #3156) on Thursday, August 7 at 9:15 a.m. in room 139. In this session, Bierdz will discuss how Riverside Medical Center uses Imprivata OneSign to enable fast, secure access to its McKesson EMR system and other clinical applications. Bierdz will also walk attendees through the complete process of implementing an SSO solution, from the initial selection to maximizing the benefits. Attendees will gain an understanding of the costs and benefits of SSO applications and also see a live demonstration of Imprivata OneSign.

About Imprivata
Imprivata is a leading provider of authentication and access management solutions for the healthcare industry. Imprivata’s single sign-on, authentication management and secure communications solutions enable fast, secure and more efficient access to healthcare information technology systems to address multiple security challenges and improve provider productivity for better focus on patient care. For more information, please visit http://www.imprivata.com.

Related Content

Private equity-backed cardiology group puts cloud-based technology in hands of its cardiologists
AI helps cardiologists deliver personalized healthcare—but there is still plenty of work to do
Indiana hospitals reduce nuisance alerts by 77% with medication decision support software
Leveraging machine learning to rapidly create clinical AI algorithms
How medication reconciliation data consolidation in the EHR enables better patient care
How are the best in KLAS Health IT vendor rankings created?

Around the web

Cardiovascular Business
Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Cardiovascular Business
FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup